APO Research
Talk to an analyst

APO RESEARCH · REPORT

Gonadotropin-releasing Hormone Agonist Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Gonadotropin-releasing Hormone Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

2 January 2026188 pages

Choose your research edition.

Industry ResearchGonadotropin-releasing Hormone Agonist Drugs Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Gonadotropin-releasing Hormone Agonist Drugs Industry Growth and Trends Forecast to 203294 pages · $3,450 USDMarket StructureGlobal Gonadotropin-releasing Hormone Agonist Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032188 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Gonadotropin-releasing Hormone Agonist Drugs Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Gonadotropin-releasing Hormone Agonist Drugs Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Gonadotropin-releasing Hormone Agonist Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Gonadotropin-releasing Hormone Agonist Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Gonadotropin-releasing Hormone Agonist Drugs include Endo, Ferring, Ipsen, LIVZON, TerSera Therapeutics, AstraZeneca, AbbVie, Sanofi and Takeda, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Gonadotropin-releasing Hormone Agonist Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Gonadotropin-releasing Hormone Agonist Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Gonadotropin-releasing Hormone Agonist Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Gonadotropin-releasing Hormone Agonist Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Gonadotropin-releasing Hormone Agonist Drugs Segment by Company

Endo

Ferring

Ipsen

LIVZON

TerSera Therapeutics

AstraZeneca

AbbVie

Sanofi

Takeda

Gonadotropin-releasing Hormone Agonist Drugs Segment by Type

Histrelin

Taltirelin

Leuprorelin

Goserelin

Other

Gonadotropin-releasing Hormone Agonist Drugs Segment by Application

Hospital

Pharmacy

Other

Gonadotropin-releasing Hormone Agonist Drugs Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Gonadotropin-releasing Hormone Agonist Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Gonadotropin-releasing Hormone Agonist Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Gonadotropin-releasing Hormone Agonist Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Gonadotropin-releasing Hormone Agonist Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Gonadotropin-releasing Hormone Agonist Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Gonadotropin-releasing Hormone Agonist Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Gonadotropin-releasing Hormone Agonist Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Gonadotropin-releasing Hormone Agonist Drugs Industry Trends Table 2. Gonadotropin-releasing Hormone Agonist Drugs Industry Drivers Table 3. Gonadotropin-releasing Hormone Agonist Drugs Industry Opportunities and Challenges Table 4. Gonadotropin-releasing Hormone Agonist Drugs Industry Restraints Table 5. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Manufacturers Table 9. Global Gonadotropin-releasing Hormone Agonist Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Gonadotropin-releasing Hormone Agonist Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Gonadotropin-releasing Hormone Agonist Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Gonadotropin-releasing Hormone Agonist Drugs Manufacturers, Product Type & Application Table 13. Global Gonadotropin-releasing Hormone Agonist Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Gonadotropin-releasing Hormone Agonist Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Histrelin Table 17. Major Manufacturers of Taltirelin Table 18. Major Manufacturers of Leuprorelin Table 19. Major Manufacturers of Goserelin Table 20. Major Manufacturers of Other Table 21. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021-2026) & (K Units) Table 23. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2027-2032) & (K Units) Table 24. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Type (2021-2026) Table 25. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Type (2027-2032) Table 26. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2021-2026) & (K Units) Table 28. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2027-2032) & (K Units) Table 29. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Type (2021-2026) Table 30. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Hospital Table 32. Major Manufacturers of Pharmacy Table 33. Major Manufacturers of Other Table 34. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021-2026) & (K Units) Table 36. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2027-2032) & (K Units) Table 37. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Application (2021-2026) Table 38. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Application (2027-2032) Table 39. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2021-2026) & (K Units) Table 41. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2027-2032) & (K Units) Table 42. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Application (2021-2026) Table 43. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Application (2027-2032) Table 44. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2021-2026) & (K Units) Table 46. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Region (2021-2026) Table 47. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026) & (K Units) Table 51. North America Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032) & (K Units) Table 52. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026) & (K Units) Table 54. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2027-2032) & (K Units) Table 61. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Region (2021-2026) Table 65. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Region (2027-2032) Table 66. Endo Company Information Table 67. Endo Business Overview Table 68. Endo Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Endo Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 70. Endo Recent Development Table 71. Ferring Company Information Table 72. Ferring Business Overview Table 73. Ferring Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Ferring Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 75. Ferring Recent Development Table 76. Ipsen Company Information Table 77. Ipsen Business Overview Table 78. Ipsen Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Ipsen Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 80. Ipsen Recent Development Table 81. LIVZON Company Information Table 82. LIVZON Business Overview Table 83. LIVZON Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. LIVZON Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 85. LIVZON Recent Development Table 86. TerSera Therapeutics Company Information Table 87. TerSera Therapeutics Business Overview Table 88. TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 90. TerSera Therapeutics Recent Development Table 91. AstraZeneca Company Information Table 92. AstraZeneca Business Overview Table 93. AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 95. AstraZeneca Recent Development Table 96. AbbVie Company Information Table 97. AbbVie Business Overview Table 98. AbbVie Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. AbbVie Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 100. AbbVie Recent Development Table 101. Sanofi Company Information Table 102. Sanofi Business Overview Table 103. Sanofi Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Sanofi Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 105. Sanofi Recent Development Table 106. Takeda Company Information Table 107. Takeda Business Overview Table 108. Takeda Gonadotropin-releasing Hormone Agonist Drugs Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Takeda Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio Table 110. Takeda Recent Development Table 111. Key Raw Materials Table 112. Raw Materials Key Suppliers Table 113. Gonadotropin-releasing Hormone Agonist Drugs Distributors List Table 114. Gonadotropin-releasing Hormone Agonist Drugs Customers List Table 115. Research Programs/Design for This Report Table 116. Authors List of This Report Table 117. Secondary Sources Table 118. Primary Sources List of Figures Figure 1. Gonadotropin-releasing Hormone Agonist Drugs Product Image Figure 2. Global Gonadotropin-releasing Hormone Agonist Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Gonadotropin-releasing Hormone Agonist Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Gonadotropin-releasing Hormone Agonist Drugs Sales (2021-2032) & (K Units) Figure 5. Global Gonadotropin-releasing Hormone Agonist Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Gonadotropin-releasing Hormone Agonist Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Histrelin Image Figure 9. Taltirelin Image Figure 10. Leuprorelin Image Figure 11. Goserelin Image Figure 12. Other Image Figure 13. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Type (2021-2032) Figure 16. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Type (2021-2032) Figure 19. Hospital Image Figure 20. Pharmacy Image Figure 21. Other Image Figure 22. Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Application (2021-2032) Figure 25. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Application (2021-2032) Figure 28. North America Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2021-2032) Figure 30. U.S. Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2021-2032) Figure 35. Germany Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2021-2032) Figure 42. China Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Country (2021-2032) Figure 50. Brazil Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Gonadotropin-releasing Hormone Agonist Drugs Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032) & (US$ Million) Figure 61. North America Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032) & (US$ Million) Figure 63. Europe Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Gonadotropin-releasing Hormone Agonist Drugs Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Gonadotropin-releasing Hormone Agonist Drugs Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Histrelin
  • Taltirelin
  • Leuprorelin
  • Goserelin
  • Other
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Endo
  • Ferring
  • Ipsen
  • LIVZON
  • TerSera Therapeutics
  • AstraZeneca
  • AbbVie
  • Sanofi
  • Takeda

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Gonadotropin-releasing Hormone Agonist Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Gonadotropin-releasing Hormone Agonist Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Gonadotropin-releasing Hormone Agonist Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Gonadotropin-releasing Hormone Agonist Drugs Market Dynamics
  1. 2.1 Gonadotropin-releasing Hormone Agonist Drugs Industry Trends
  2. 2.2 Gonadotropin-releasing Hormone Agonist Drugs Industry Drivers
  3. 2.3 Gonadotropin-releasing Hormone Agonist Drugs Industry Opportunities and Challenges
  4. 2.4 Gonadotropin-releasing Hormone Agonist Drugs Industry Restraints
3 Gonadotropin-releasing Hormone Agonist Drugs Market by Manufacturers
  1. 3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Gonadotropin-releasing Hormone Agonist Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Gonadotropin-releasing Hormone Agonist Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Gonadotropin-releasing Hormone Agonist Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Gonadotropin-releasing Hormone Agonist Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Gonadotropin-releasing Hormone Agonist Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Gonadotropin-releasing Hormone Agonist Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Gonadotropin-releasing Hormone Agonist Drugs Tier 1, Tier 2, and Tier 3
4 Gonadotropin-releasing Hormone Agonist Drugs Market by Type
  1. 4.1 Gonadotropin-releasing Hormone Agonist Drugs Type Introduction
  2. 4.1.1 Histrelin
  3. 4.1.2 Taltirelin
  4. 4.1.3 Leuprorelin
  5. 4.1.4 Goserelin
  6. 4.1.5 Other
  7. 4.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type
  8. 4.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Type (2021-2032)
  10. 4.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Type (2021-2032)
  11. 4.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type
  12. 4.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Type (2021-2032)
  14. 4.3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Type (2021-2032)
5 Gonadotropin-releasing Hormone Agonist Drugs Market by Application
  1. 5.1 Gonadotropin-releasing Hormone Agonist Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application
  6. 5.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Application (2021-2032)
  8. 5.2.3 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Market Share by Application (2021-2032)
  9. 5.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application
  10. 5.3.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Application (2021-2032)
  12. 5.3.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Application (2021-2032)
6 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region
  1. 6.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Gonadotropin-releasing Hormone Agonist Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Gonadotropin-releasing Hormone Agonist Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region
  1. 7.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region
  2. 7.1.1 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Gonadotropin-releasing Hormone Agonist Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032)
  8. 7.2.2 North America Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Gonadotropin-releasing Hormone Agonist Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Endo
  2. 8.1.1 Endo Company Information
  3. 8.1.2 Endo Business Overview
  4. 8.1.3 Endo Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Endo Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  6. 8.1.5 Endo Recent Developments
  7. 8.2 Ferring
  8. 8.2.1 Ferring Company Information
  9. 8.2.2 Ferring Business Overview
  10. 8.2.3 Ferring Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Ferring Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  12. 8.2.5 Ferring Recent Developments
  13. 8.3 Ipsen
  14. 8.3.1 Ipsen Company Information
  15. 8.3.2 Ipsen Business Overview
  16. 8.3.3 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Ipsen Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  18. 8.3.5 Ipsen Recent Developments
  19. 8.4 LIVZON
  20. 8.4.1 LIVZON Company Information
  21. 8.4.2 LIVZON Business Overview
  22. 8.4.3 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LIVZON Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  24. 8.4.5 LIVZON Recent Developments
  25. 8.5 TerSera Therapeutics
  26. 8.5.1 TerSera Therapeutics Company Information
  27. 8.5.2 TerSera Therapeutics Business Overview
  28. 8.5.3 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 TerSera Therapeutics Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  30. 8.5.5 TerSera Therapeutics Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 AbbVie
  38. 8.7.1 AbbVie Company Information
  39. 8.7.2 AbbVie Business Overview
  40. 8.7.3 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 AbbVie Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  42. 8.7.5 AbbVie Recent Developments
  43. 8.8 Sanofi
  44. 8.8.1 Sanofi Company Information
  45. 8.8.2 Sanofi Business Overview
  46. 8.8.3 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  48. 8.8.5 Sanofi Recent Developments
  49. 8.9 Takeda
  50. 8.9.1 Takeda Company Information
  51. 8.9.2 Takeda Business Overview
  52. 8.9.3 Takeda Gonadotropin-releasing Hormone Agonist Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Takeda Gonadotropin-releasing Hormone Agonist Drugs Product Portfolio
  54. 8.9.5 Takeda Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Gonadotropin-releasing Hormone Agonist Drugs Value Chain Analysis
  2. 9.1.1 Gonadotropin-releasing Hormone Agonist Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Gonadotropin-releasing Hormone Agonist Drugs Production Mode & Process
  6. 9.2 Gonadotropin-releasing Hormone Agonist Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Gonadotropin-releasing Hormone Agonist Drugs Distributors
  9. 9.2.3 Gonadotropin-releasing Hormone Agonist Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst